Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585871 | 0.80 | CRBN (0.71) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL8521910 | 0.80 | CRBN (1.00) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL6819070 | 0.77 | CRBN (0.71) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL24890784 | 0.77 | HTT (0.56) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL24890781 | 0.77 | HTT (0.56) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL19605721 | 0.77 | CRBN (0.66) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL20805403 | 0.77 | CRBN (0.66) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL31323585 | 0.74 | CRBN (0.62) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL21946926 | 0.74 | HTT (0.60) | CRBNDDB1HTTGAAPOLB | |
| SCHEMBL24440196 | 0.74 | CRBN (0.49) | CRBNDDB1HTTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2022266248-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CRBN 188/4885DDB1 390/4885HTT 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.